Taysha Gene Therapies (TSHA) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Taysha Gene Therapies (TSHA) overview

Taysha Gene Therapies (TSHA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 9.8m and operating profit of USD -110m; the year-end share price was 5.50 USD and market capitalisation was USD 1,568m. Taysha Gene Therapies is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Taysha Gene Therapies's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 247mFY 2025
Share price5.50 USDFY 2025 year end
RevenueUSD 9.8mFY 2025
Operating profitUSD -110mFY 2025
Net earningsUSD -109mFY 2025
Market capitalisationUSD 1,568mFY 2025 year end

About Taysha Gene Therapies

Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is being evaluated as a treatment for Rett syndrome in clinical trials involving adolescent, adult and pediatric females. The company’s work focuses on developing treatments for patients with severe neurological disease.

Generate the Taysha Gene Therapies report

Taysha Gene Therapies is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Taysha Gene Therapies and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Taysha Gene Therapies

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.